Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2023 16:02 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial...
November 07, 2023 16:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

-- CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 -- ...
November 06, 2023 08:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

-- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading...
November 01, 2023 16:05 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
October 18, 2023 08:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

-- AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 -- -- CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the...
September 27, 2023 08:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer

BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
August 29, 2023 16:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
August 08, 2023 16:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1...
July 13, 2023 23:15 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of...
July 13, 2023 16:03 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Announces Proposed Public Offering of Common Stock

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has...